SC-002

N/A

Report date: 2024/02/05 13:57:28

Base Information

Drug NameSC-002

Drug Alias NameSC-002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTumor-associated antigen modulatorsImmunomodulators

TargetsTumor-associated antigen

Therapy Area/IndicationsSmall Cell Lung Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesStemcentrx Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesStemcentrx Inc

Active IndicationsN/A

Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A